Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.580
-0.170 (-6.18%)
At close: Sep 25, 2026, 4:00 PM EDT
2.626
+0.046 (1.80%)
After-hours: Sep 25, 2026, 7:13 PM EDT
Editas Medicine Revenue
Editas Medicine had revenue of $11.89M in the quarter ending June 30, 2026, with 232.31% growth. This brings the company's revenue in the last twelve months to $47.01M, up 20.83% year-over-year. In the year 2025, Editas Medicine had annual revenue of $40.52M with 25.39% growth.
Revenue (ttm)
$47.01M
Revenue Growth
+20.83%
P/S Ratio
8.43
Revenue / Employee
$540,287
Employees
87
Market Cap
396.24M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 40.52M | 8.21M | 25.39% |
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
| Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
| Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
| Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
| Dec 31, 2015 | 1.63M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 116.93M |
| Prothena Corporation | 54.53M |
| Scribe Therapeutics | 33.30M |
| Arcturus Therapeutics Holdings | 29.37M |
| Prelude Therapeutics | 22.42M |
| Opus Genetics | 9.86M |
EDIT News
- 2 days ago - Editas slips amid pressure on gene-editing sector after Anthropic update - TheFly
- 2 days ago - Editas Medicine upgraded to Buy at Guggenheim on EDIT-401 potential - TheFly
- 2 days ago - Editas Medicine upgraded to Buy from Neutral at Guggenheim - TheFly
- 15 days ago - Editas Medicine Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 16 days ago - Editas Medicine Reports Inducement Grants to New Chief Medical Officer - GlobeNewsWire
- 17 days ago - Editas Medicine Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 17 days ago - Editas Medicine appoints Dan Ory as chief medical officer - TheFly
- 17 days ago - Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - GlobeNewsWire